UNITED THERAPEUTICS Corp
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
UTHR$588.61+1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| Three Months Ended September 30, 2026 | |||||||
|---|---|---|---|---|---|---|---|
| (Unaudited) | |||||||
| Common Stock · AdditionalPaid-inCapital · AccumulatedOtherComprehensive(Loss) Income · TreasuryStock · Retained Earnings · Stockholders’ Equity | |||||||
| Shares · Amount | |||||||
| Balance, July 1, 2026 | 78.0 | $0.8 | $2,895.8 | $(16.2) | $(5,644.9) | $9,164.8 | $6,400.3 |
| Net income | — | — | — | — | — | 258.6 | 258.6 |
| Other comprehensive loss, net of tax | — | — | — | (14.1) | — | — | (14.1) |
| Shares issued under employee stock purchase plan (ESPP) | — | — | 5.0 | — | — | — | 5.0 |
| Restricted stock units (RSUs) withheld for taxes | — | — | (0.8) | — | — | — | (0.8) |
| Share repurchases | — | — | (7.4) | — | (492.6) | — | (500.0) |
| Excise tax on net share repurchases | — | — | — | — | (1.4) | — | (1.4) |
| Exercise of stock options | 0.7 | — | 87.4 | — | — | — | 87.4 |
| Share-based compensation | — | — | 41.0 | — | — | — | 41.0 |
| Balance, September 30, 2026 | 78.7 | $0.8 | $3,021.0 | $(30.3) | $(6,138.9) | $9,423.4 | $6,276.0 |
| Three Months Ended September 30, 2025 | |||||||
|---|---|---|---|---|---|---|---|
| (Unaudited) | |||||||
| Common Stock · AdditionalPaid-inCapital · AccumulatedOtherComprehensive(Loss) Income · TreasuryStock · Retained Earnings · Stockholders’ Equity | |||||||
| Shares · Amount | |||||||
| Balance, July 1, 2025 | 75.4 | $0.8 | $2,793.4 | $— | $(3,474.5) | $7,853.9 | $7,173.6 |
| Net income | — | — | — | — | — | 338.7 | 338.7 |
| Other comprehensive income, net of tax | — | — | — | 0.1 | — | — | 0.1 |
| Shares issued under ESPP | — | — | 4.3 | — | — | — | 4.3 |
| RSUs withheld for taxes | — | — | (0.5) | — | — | — | (0.5) |
| Share repurchases | — | — | (217.8) | — | (782.2) | — | (1,000.0) |
| Excise tax on net share repurchases | — | — | — | — | (5.3) | — | (5.3) |
| Exercise of stock options | 0.3 | — | 40.2 | — | — | — | 40.2 |
| Share-based compensation | — | — | 39.1 | — | — | — | 39.1 |
| Balance, September 30, 2025 | 75.7 | $0.8 | $2,658.7 | $0.1 | $(4,262.0) | $8,192.6 | $6,590.2 |
| 6 | United Therapeutics, a public benefit corporation |
| Nine Months Ended September 30, 2026 | |||||||
|---|---|---|---|---|---|---|---|
| (Unaudited) | |||||||
| Common Stock · AdditionalPaid-inCapital · AccumulatedOtherComprehensive(Loss) Income · TreasuryStock · Retained Earnings · Stockholders’ Equity | |||||||
| Shares · Amount | |||||||
| Balance, January 1, 2026 | 76.5 | $0.8 | $2,798.0 | $0.9 | $(4,260.4) | $8,556.9 | $7,096.2 |
| Net income | — | — | — | — | — | 866.5 | 866.5 |
| Other comprehensive loss, net of tax | — | — | — | (31.2) | — | — | (31.2) |
| Shares issued under ESPP | — | — | 10.6 | — | — | — | 10.6 |
| RSUs withheld for taxes | — | — | (59.6) | — | — | — | (59.6) |
| Share repurchases | — | — | (128.3) | — | (1,871.7) | — | (2,000.0) |
| Excise tax on net share repurchases | — | — | — | — | (6.8) | — | (6.8) |
| Common stock issued for RSUs vested | 0.1 | — | — | — | — | — | — |
| Exercise of stock options | 2.1 | — | 282.0 | — | — | — | 282.0 |
| Share-based compensation | — | — | 118.3 | — | — | — | 118.3 |
| Balance, September 30, 2026 | 78.7 | $0.8 | $3,021.0 | $(30.3) | $(6,138.9) | $9,423.4 | $6,276.0 |
| Nine Months Ended September 30, 2025 | |||||||
|---|---|---|---|---|---|---|---|
| (Unaudited) | |||||||
| Common Stock · AdditionalPaid-inCapital · AccumulatedOtherComprehensive(Loss) Income · TreasuryStock · Retained Earnings · Stockholders’ Equity | |||||||
| Shares · Amount | |||||||
| Balance, January 1, 2025 | 75.0 | $0.8 | $2,698.9 | $(3.4) | $(3,474.5) | $7,222.2 | $6,444.0 |
| Net income | — | — | — | — | — | 970.4 | 970.4 |
| Other comprehensive income, net of tax | — | — | — | 3.5 | — | — | 3.5 |
| Shares issued under ESPP | — | — | 9.2 | — | — | — | 9.2 |
| RSUs withheld for taxes | — | — | (16.0) | — | — | — | (16.0) |
| Share repurchases | — | — | (217.8) | — | (782.2) | — | (1,000.0) |
| Excise tax on net share repurchases | — | — | — | — | (5.3) | — | (5.3) |
| Common stock issued for RSUs vested | 0.1 | — | — | — | — | — | — |
| Exercise of stock options | 0.6 | — | 74.9 | — | — | — | 74.9 |
| Share-based compensation | — | — | 109.5 | — | — | — | 109.5 |
| Balance, September 30, 2025 | 75.7 | $0.8 | $2,658.7 | $0.1 | $(4,262.0) | $8,192.6 | $6,590.2 |
| Quarterly Report | 7 |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.